1. Home
  2. NRC vs CABA Comparison

NRC vs CABA Comparison

Compare NRC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Research Corporation (Delaware)

NRC

National Research Corporation (Delaware)

HOLD

Current Price

$20.96

Market Cap

474.2M

Sector

Health Care

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.80

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRC
CABA
Founded
1981
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.2M
495.7M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
NRC
CABA
Price
$20.96
$2.80
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
87.7K
2.9M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
3.86%
N/A
EPS Growth
4707.69
10.26
EPS
N/A
N/A
Revenue
$119,686,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.81
N/A
52 Week Low
$11.01
$1.26
52 Week High
$23.68
$4.23

Technical Indicators

Market Signals
Indicator
NRC
CABA
Relative Strength Index (RSI) 54.05 46.97
Support Level $17.82 $2.63
Resistance Level $22.07 $3.34
Average True Range (ATR) 1.34 0.12
MACD -0.05 0.02
Stochastic Oscillator 54.31 72.92

Price Performance

Historical Comparison
NRC
CABA

About NRC National Research Corporation (Delaware)

NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: